TY - JOUR
T1 - Helicobacter pylori phage screening
AU - Vale, Filipa F.
AU - Matos, António P.A.
AU - Carvalho, Patrícia
AU - Vtor, Jorge M.B.
PY - 2008/9
Y1 - 2008/9
N2 - Helicobacter pylori is a helical shaped Gram-negative bacterium that colonizes the human stomach. It is associated with several human pathologies, such as gastritis, peptic ulcer, and gastric cancer. The standard first-line treatment is a one week triple therapy: the association of two antibiotics, most frequently amoxicillin and clarithromycin, and a proton pump inhibior. Despite the evolution of the treatment strategy, quadruple therapy, there is an increasing percentage of failure of the antibiotic therapy, due to antibiotics resistance. Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections and H. pylori is a good target. However there are no available phage collections, and H. pylori phages description is diminutive on literature.
AB - Helicobacter pylori is a helical shaped Gram-negative bacterium that colonizes the human stomach. It is associated with several human pathologies, such as gastritis, peptic ulcer, and gastric cancer. The standard first-line treatment is a one week triple therapy: the association of two antibiotics, most frequently amoxicillin and clarithromycin, and a proton pump inhibior. Despite the evolution of the treatment strategy, quadruple therapy, there is an increasing percentage of failure of the antibiotic therapy, due to antibiotics resistance. Phage therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections and H. pylori is a good target. However there are no available phage collections, and H. pylori phages description is diminutive on literature.
UR - http://www.scopus.com/inward/record.url?scp=53349128312&partnerID=8YFLogxK
U2 - 10.1017/S1431927608089721
DO - 10.1017/S1431927608089721
M3 - Article
AN - SCOPUS:53349128312
SN - 1431-9276
VL - 14
SP - 150
EP - 151
JO - Microscopy and Microanalysis
JF - Microscopy and Microanalysis
IS - SUPPL. 3
ER -